{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T17:43:17Z","timestamp":1767202997630,"version":"build-2238731810"},"reference-count":18,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,11,23]],"date-time":"2020-11-23T00:00:00Z","timestamp":1606089600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p>\n                    <jats:bold>Background:<\/jats:bold>\n                    Human immunodeficiency viruses (HIV) infection is associated with a broad range of neurological manifestations, including opsoclonus-myoclonus ataxia syndrome (OMAS) occurring in primary infection, immune reconstitution syndrome or in case of opportunistic co-infection.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Case:<\/jats:bold>\n                    We report the exceptional case of a 43-year-old female under HIV treatment for 10 years who presented initially with suspected epileptic seizure. Although the clinical picture slightly improved under anti-epileptic treatment, it was rapidly attributed to OMAS. The patient exhibited marked opsoclonus, mild dysarthria, upper limbs intermittent myoclonus, ataxia in 4 limbs, truncal ataxia, and a severe gait ataxia (SARA score: 34). The diagnostic work-up showed radiological and biological signs of central nervous system (CNS) inflammation and cerebral venous sinus thromboses. The HIV viral load was higher in cerebrospinal fluid (CSF) than in the blood (4,560 copies\/ml vs. 76 copies\/ml). She was treated for 5 days with pulsed corticotherapy. Dolutegravir and anticoagulation administration were initiated. Follow-ups at 2 and 4 months showed a dramatic improvement of clinical neurologic status (SARA score at 4 months: 1), reduction of CNS inflammation and revealed undetectable CSF and serum viral loads.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    This case underlines the importance of the evaluation of the CSF viral load in HIV patients developing OMAS and suggests CSF HIV RNA escape as a novel cause for OMAS.\n                  <\/jats:p>","DOI":"10.3389\/fneur.2020.585527","type":"journal-article","created":{"date-parts":[[2020,11,23]],"date-time":"2020-11-23T01:41:46Z","timestamp":1606095706000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["CSF HIV RNA Escape in Opsoclonus-Myoclonus-Ataxia Syndrome: Case Report and Review of the Literature"],"prefix":"10.3389","volume":"11","author":[{"given":"Pierre","family":"Cabaraux","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arthur","family":"Poncelet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00e9rome","family":"Honnorat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Remy","family":"Demeester","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soraya","family":"Cherifi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Manto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2020,11,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1097\/QAD.0000000000001796","article-title":"Global HIV neurology: a comprehensive review","volume":"33","author":"Thakur","year":"2019","journal-title":"AIDS."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1097\/qad.0b013e328355e6b2","article-title":"Cerebrospinal fluiin patients on antiretroviral therapy with well-controlled plasma viral load","volume":"26","author":"Peluso","year":"2012","journal-title":"AIDS."},{"key":"B3","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1007\/s11904-015-0267-7","article-title":"Cerebrospinal fluid HIV escape from antiretroviral therapy","volume":"12","author":"Ferretti","year":"2015","journal-title":"Curr HIV\/AIDS Rep."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1007\/s00415-018-9138-7","article-title":"Update on opsoclonus\u2013myoclonus syndrome in adults","volume":"266","author":"Oh","year":"2018","journal-title":"J Neurol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s13365-017-0603-3","article-title":"HIV-associated opsoclonus-myoclonus-ataxia syndrome: early infection, immune reconstitution syndrome or secondary to other diseases?","volume":"24","author":"Guedes","year":"2017","journal-title":"J NeuroVirol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1097\/wco.0b013e3280126b51","article-title":"An update on opsoclonus","volume":"20","author":"Wong","year":"2007","journal-title":"Curr Opin Neurol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1212\/01.wnl.0000219042.60538.92","article-title":"Scale for the assessment and rating of ataxia: development of a new clinical scale","volume":"66","author":"Schmitz-H\u00fcbsch","year":"2006","journal-title":"Neurology"},{"key":"B8","doi-asserted-by":"publisher","first-page":"33","DOI":"10.2174\/1570159X16666180917105033","article-title":"Immune-mediated cerebellar ataxias: practical guidelines and therapeutic challenges","volume":"17","author":"Mitoma","year":"2019","journal-title":"Curr Neuropharmacol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"S266","DOI":"10.1016\/j.pmrj.2016.07.494","article-title":"Poster 324 opsoclonus-myoclonus-ataxia syndrome and HIV infection","volume":"8","author":"Wang","year":"2016","journal-title":"Case Rep PM&R."},{"key":"B10","doi-asserted-by":"publisher","first-page":"S107","DOI":"10.1097\/qad.0000000000002252","article-title":"Defining cerebrospinal fluid HIV RNA escape","volume":"33","author":"Winston","year":"2019","journal-title":"AIDS."},{"key":"B11","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S2055-6640(20)30879-7","article-title":"Highlights of the Global HIV-1 CSF Escape Consortium Meeting, 9 June 2016, Bethesda, MD, USA","volume":"2","author":"Joseph","year":"2016","journal-title":"J Virus Erad."},{"key":"B12","doi-asserted-by":"publisher","first-page":"10830","DOI":"10.1128\/JVI.79.16.10830-10834.2005","article-title":"Increased human immunodeficiency virus type 1 (HIV-1) env compartmentalization in the presence of HIV-1-associated dementia","volume":"79","author":"Ritola","year":"2005","journal-title":"J Virol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1093\/cid\/ciy267","article-title":"Impact of antiretroviral regimens on cerebrospinal fluid viral escape in a prospective multicohort study of antiretroviral therapy-experienced Human Immunodeficiency Virus-1\u2013infected adults in the United States","volume":"67","author":"Mukerji","year":"2018","journal-title":"Clin Infect Dis."},{"key":"B14","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s13365-015-0404-5","article-title":"Central nervous system penetration effectiveness of antiretroviral drugs and neuropsychological impairment in the Ontario HIV Treatment Network Cohort Study","volume":"22","author":"Carvalhal","year":"2015","journal-title":"J NeuroVirol."},{"key":"B15","first-page":"137","article-title":"Central nervous system complications in HIV disease: HIV-associated neurocognitive disorder","volume":"19","author":"Letendre","year":"2011","journal-title":"Top Antivir Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1111\/j.1468-1293.2010.00869.x","article-title":"HIV and risk of venous thromboembolism: a Danish nationwide population-based cohort study","volume":"12","author":"Rasmussen","year":"2010","journal-title":"HIV Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.jns.2017.04.034","article-title":"Profile of 26 HIV seropositive individuals with cerebral venous thrombosis","volume":"378","author":"Netravathi","year":"2017","journal-title":"J Neurol Sci."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1001\/jamaneurol.2019.2764","article-title":"Safety and efficacy of dabigatran etexilate vs. dose-adjusted warfarin in patients with cerebral venous thrombosis","volume":"76","author":"Ferro","year":"2019","journal-title":"JAMA Neurol."}],"updated-by":[{"DOI":"10.3389\/fneur.2021.665996","type":"corrigendum","label":"Corrigendum","source":"publisher","updated":{"date-parts":[[2021,3,17]],"date-time":"2021-03-17T00:00:00Z","timestamp":1615939200000}}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2020.585527\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,17]],"date-time":"2021-03-17T06:39:44Z","timestamp":1615963184000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2020.585527\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,23]]},"references-count":18,"alternative-id":["10.3389\/fneur.2020.585527"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2020.585527","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,23]]},"article-number":"585527"}}